Primary Effusion Lymphoma — Trials

Primary Effusion Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

14 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 7
Recruiting: 2
Ph III recruiting: 0
Growth YoY: —
Industry share: 14%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (2)

clinicaltrialsPublishedShowing 1–9 of 9 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00006518	Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer	recruiting	—	1,029	National Cancer Institute (NCI)NIH	1	Sep 28, 2026	clinicaltrials
NCT05907759	Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease	recruiting	Phase 2	40	National Cancer Institute (NCI)NIH	1	Sep 25, 2026